biostudies-literatureMaturana MJANID FONDAP apoyo3333https://www.ebi.ac.uk/biostudies/studies/S-EPMC11989948biostudies-literatureUnknown26(7)Restrictions resulting from the COVID-19 pandemic abruptly reversed the slow decline of the diagnosis and mortality rates of gastric cancer (GC). This scenario highlights the importance of developing cost-effective methods for mass screening and evaluation of treatment response. In this study, we evaluated a non-invasive method based on the circulating methylated cell-free DNA (cfDNA) of Reprimo (<i>RPRM</i>), a tumor suppressor gene associated with the development of GC. Methylated <i>RPRM</i> cfDNA was analyzed in three de-identified cohorts: Cohort 1 comprised 81 participants with GC and 137 healthy donors (HDs); Cohort 2 comprised 27 participants with GC undergoing gastrectomy and/or chemotherapy analyzed at the beginning and after three months of treatment; and Cohort 3 comprised 1105International journal of molecular sciencesMethylated Reprimo Cell-Free DNA as a Non-Invasive Biomarker for Gastric Cancer.PMC119899481523A0008Santoro PMAlarcon MABlanco AGarrido MCalvo-Belmar AMaturana MJAravena EBarrientos CCorvalan AHPadilla OOlivares WArmisen RfalseMethylated Reprimo Cell-Free DNA as a Non-Invasive Biomarker for Gastric Cancer.Restrictions resulting from the COVID-19 pandemic abruptly reversed the slow decline of the diagnosis and mortality rates of gastric cancer (GC). This scenario highlights the importance of developing cost-effective methods for mass screening and evaluation of treatment response. In this study, we evaluated a non-invasive method based on the circulating methylated cell-free DNA (cfDNA) of Reprimo (<i>RPRM</i>), a tumor suppressor gene associated with the development of GC. Methylated <i>RPRM</i> cfDNA was analyzed in three de-identified cohorts: Cohort 1 comprised 81 participants with GC and 137 healthy donors (HDs); Cohort 2 comprised 27 participants with GC undergoing gastrectomy and/or chemotherapy analyzed at the beginning and after three months of treatment; and Cohort 3 comprised 11052025-01-01T00:00:00Z2025 Apr2025-07-07T03:10:10.046Z2025-07-07T03:10:10.046ZS-EPMC119899484024416410.3390/ijms26073333